ITC Favors Allergan Partner Medytox Over Daewoong in Botulinum Toxin Strain Dispute

Posted By American Med Spa Association, Friday, July 10, 2020

The U.S. International Trade Commission (ITC) has sided with South Korean drugmaker Medytox Inc. in a dispute, saying its local rival Daewoong Pharmaceutical Co. stole trade secrets on a botulinum toxin strain, industry officials here said Tuesday.
In its preliminary verdict, the ITC also advised that imports of Daewoong Pharmaceutical's botulinum toxin products be banned in the United States over the next 10 years.

Read more at the Yonhap News Agency >>